Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Work In Process (2021 - 2025)

Historic Work In Process for Aytu Biopharma (AYTU) over the last 5 years, with Q4 2025 value amounting to $1.8 million.

  • Aytu Biopharma's Work In Process fell 4147.6% to $1.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 million, marking a year-over-year decrease of 4147.6%. This contributed to the annual value of $1.4 million for FY2025, which is 7587.77% down from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Work In Process is $1.8 million, which was down 4147.6% from $862000.0 recorded in Q3 2025.
  • Aytu Biopharma's Work In Process' 5-year high stood at $5.7 million during Q2 2024, with a 5-year trough of $862000.0 in Q3 2025.
  • In the last 5 years, Aytu Biopharma's Work In Process had a median value of $2.8 million in 2022 and averaged $2.8 million.
  • As far as peak fluctuations go, Aytu Biopharma's Work In Process soared by 9367.39% in 2024, and later tumbled by 7587.77% in 2025.
  • Over the past 5 years, Aytu Biopharma's Work In Process (Quarter) stood at $2.2 million in 2021, then increased by 28.99% to $2.8 million in 2022, then fell by 4.6% to $2.7 million in 2023, then grew by 16.04% to $3.1 million in 2024, then crashed by 41.48% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q4 2025, $862000.0 for Q3 2025, and $1.4 million during Q2 2025.